Amicus Therapeutics, Inc.
Amicus announces merger with BioMarin at $14.50 per share.
1 source·19/12, 14:26·sec.gov
Upcoming earnings announcement and conference call scheduled.
1 source·04/11, 12:44·sec.gov
10-Q form submitted!
1 source·31/07, 20:08·sec.gov
Financial results announcement and conference call details.
1 source·31/07, 11:07·sec.gov
Stockholders elected directors and approved incentive plan.
1 source·05/06, 20:02·sec.gov
Amicus to present at investor conferences in June 2025.
1 source·30/05, 11:20·finviz.com
Amicus Therapeutics secures promising licensing agreement for growth.
1 source·13/05, 12:53·finviz.com
Amicus Therapeutics to present at healthcare conference.
1 source·07/05, 11:18·finviz.com
10-Q form submitted!
1 source·01/05, 20:05·sec.gov
Amicus reports Q1 loss, misses earnings expectations.
1 source·01/05, 11:30·yahoo.com
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
·finviz.com·30/05, 11:20
Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?
·finviz.com·13/05, 12:53
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
·finviz.com·07/05, 11:18
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
·yahoo.com·01/05, 11:11
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
·globenewswire.com·30/04, 23:19
Is ??Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In?
·finviz.com·11/04, 12:38
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?
·finviz.com·08/04, 14:08